🤖 AI Summary
To address the challenges of retraining requirements and poor clinical adaptability in cross-center deployment of medical AI models, this paper introduces GlobeReady—the first zero-shot, multimodal (fundus/OCT) diagnostic platform designed specifically for ophthalmologists, enabling plug-and-play usage without fine-tuning, retraining, or technical intervention. It innovatively employs a training-free local feature enhancement strategy to mitigate domain shifts across centers and populations, and integrates quantifiable confidence-aware diagnosis with out-of-distribution (OOD) detection to ensure clinical safety. Evaluated on multicenter datasets from China, Vietnam, and the UK, GlobeReady achieves fundus image accuracy of 93.9–98.5% and OCT accuracy of 87.2–92.7%; cross-center accuracies reach 88.9%, 86.3%, and 90.2%, respectively. With confidence gating, accuracy improves to 94.9–99.4%, and OOD detection F1-scores attain 86.3% and 90.6%. Clinician evaluation yields a mean score of 4.6/5.
📝 Abstract
Artificial intelligence (AI) shows remarkable potential in medical imaging diagnostics, but current models typically require retraining when deployed across different clinical centers, limiting their widespread adoption. We introduce GlobeReady, a clinician-friendly AI platform that enables ocular disease diagnosis without retraining/fine-tuning or technical expertise. GlobeReady achieves high accuracy across imaging modalities: 93.9-98.5% for an 11-category fundus photo dataset and 87.2-92.7% for a 15-category OCT dataset. Through training-free local feature augmentation, it addresses domain shifts across centers and populations, reaching an average accuracy of 88.9% across five centers in China, 86.3% in Vietnam, and 90.2% in the UK. The built-in confidence-quantifiable diagnostic approach further boosted accuracy to 94.9-99.4% (fundus) and 88.2-96.2% (OCT), while identifying out-of-distribution cases at 86.3% (49 CFP categories) and 90.6% (13 OCT categories). Clinicians from multiple countries rated GlobeReady highly (average 4.6 out of 5) for its usability and clinical relevance. These results demonstrate GlobeReady's robust, scalable diagnostic capability and potential to support ophthalmic care without technical barriers.